{
  "docId": "019dd923-622b-71dc-a6d9-fc4318e06f9b",
  "docSlug": "6ded4b1cfe2c",
  "documentTitle": "Bristol-Myers Squibb Company (BMY)",
  "authorId": "03_Starboard_Value",
  "authorName": "Starboard Value",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2019-03-18 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 117,
  "pageCount": 197,
  "prevPage": 116,
  "nextPage": 118,
  "slideType": "timeline",
  "function": "diagnose_problem",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a timeline to frame the late entry as a strategic failure or disadvantage.",
  "elementsJson": [
    "headline_text",
    "subtitle_text",
    "timeline_visual",
    "callout_box",
    "quote_block"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6d9-fc4318e06f9b/117",
  "deckHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b#slide-117",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Given the required education of the medical community on new CAR-T therapies, speed to market is key",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-0f19-73dd-8e9c-527c40f505e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Timeline of FDA approvals from 2017 to 2020",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ca16c16-927f-4fbf-9d93-e1fc117527f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "If Celgene's therapies make it to market, they will be years behind the current therapies from Gilead (YESCARTA) and Novartis (KYMRIAH).",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d5fded0-1b8c-4a17-9e0d-7956e6879b15",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.5,
        "x": 0.4,
        "y": 0.65
      },
      "kind": "quote",
      "text": "Celgene has guided a 2020 approval date, and $3B in potential peak revenues. While we view the likelihood of a 2020 approval as high, we believe the potential peak sales will be closer to $1.2B.",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d4ecb37-2f43-47c4-8362-7a7679588f34",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“Celgene has guided a 2020 approval date, and $3B in potential peak revenues. While we view the likelihood of a 2020 approval as high, we believe the potential peak sales will be closer to $1.2B. As a third to market product in a developing market wherein sales have been modest thus far, this guidance is aggressive…” — Cowen, February 2019",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-0f19-73dd-8e9c-551b39656b55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.05,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "Source: Public company filings, press releases, Wall Street research.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e550c4a-4d1c-49f0-b394-8338502bff56",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "title",
      "text": "Given the required education of the medical community on new CAR-T therapies, speed to market is key",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f70a6954-cfa5-46df-a43d-ab904b09967f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Which Further Exacerbates Celgene's Disadvantage From Being at Least 3rd to Market if JCAR017 Is Launched",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5935788-7224-4186-9ff1-60d8cac94060",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "b6ca5d20-dbde-4a99-bbc7-daa8061c81ec",
      "evidence": "Visual representation of events over time",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}